Form 4: Axsome COO Sells Shares After Option Exercise

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, exercised stock options and subsequently sold 45,783 shares of common stock on September 16, 2025, under a pre-approved 10b5-1 plan.

Summary

• Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc. (AXSM), engaged in transactions on September 16, 2025.
• He exercised stock options for 25,000 shares of common stock at an exercise price of $4.95 per share.
• He also exercised stock options for 15,000 shares of common stock at an exercise price of $4.85 per share.
• These option exercises were necessary as the options were set to expire due to reaching their 10-year expiration date.
• Following the exercises, he sold 5,783 shares of common stock at $116.19 per share.
• He subsequently sold an additional 40,000 shares of common stock at a weighted average price of $114.23 per share, with individual sale prices ranging from $112.93 to $116.87.
• All transactions were conducted pursuant to a pre-approved Rule 10b5-1 plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan and involved the exercise of expiring options, suggesting a routine liquidity event rather than a bearish signal. The significant profit realized by the COO is a positive for the individual.

Positives

• The sale prices of $116.19 and $114.23 are significantly higher than the exercise prices of $4.95 and $4.85, indicating substantial gains for the Chief Operating Officer.
• The transactions were executed under a pre-approved 10b5-1 plan, which suggests a planned, rather than opportunistic, sale.

Negatives

• A significant sale of 45,783 shares by a Chief Operating Officer could be perceived negatively by some investors, even if planned.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Mark L. Jacobson, Chief Operating Officer, exercised stock options and sold shares of Axsome Therapeutics, Inc. common stock.

Stakeholder Impact

• Shareholders may view the insider sale with slight caution, though the 10b5-1 plan and expiring options context mitigates negative interpretation.
• The company's stock price could experience minor fluctuations based on market perception of insider selling, but the pre-planned nature reduces the likelihood of a significant negative impact.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of expiring stock options and subsequent sale of shares under a pre-approved 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a strong buy/sell signal. Investors should consider this a planned liquidity event for the executive rather than a reflection of new information about the company's prospects. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions while awaiting more substantive company-specific news or financial results.

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Stock Options, Share Sale, Mark L. Jacobson, COO, 10b5-1 Plan